CODIGO : **173397**

NOMBRE PACIENTE : MIA ANTONELLA AREVALO SANCHEZ **SEXO :** FEMENINO

FECHA DE NACIMIENTO : 22/02/2026 **REGISTRO CIVIL:** 1,244,781,819

NOMBRE RESPONSABLE : GLEIDY LLERALDY SANCHEZ BRAVO

DOC.IDENTIDAD DE LA MADRE : 1,232,892,279

FECHA TOMA DE MUESTRA : 13/05/2026 **TIPO DE MUESTRA :** TALÓN

FECHA DE IMPRESIÓN : 16/07/2026 **PESO :** 3180

TAMIZAJE NEONATAL

ANÁLISIS MUESTRA DE SANGRE

	RESULTADO	VALORES DE REFERENCIA	INTERPRETACIÓN
TÉCNICA: Fluoroinmunoensayo (Delfia).			*Procesado en Colombia por PREGEN.*
Hemoglobinopatías	AF	Ausencia de hemoglobinas anormales	Normal
TÉCNICA: Cromatografía Liquida de Alto Rendimiento (HPLC).			*Procesado en Colombia por PREGEN.*

TAMIZAJE AMPLIADO

ESPECTROMETRIA DE MASAS EN TANDEM

Procesado en Archimedlife international medical laboratory. 1110 Vienna.

DESORDENES DE AMINOÁCIDOS			
Citrulina, Metionina, Leucina, Isoleucina, Valina, Fenilalanina, Tirosina.		Ausencia de metabolitos anormales	Normal
PERFIL DE ACILCARNITINAS			
C16,C18,C18:1,C16OH,C18:1OH,C8,C10:1,C5,C5DC,C4,C14,C14:1,C50H,C3,C5:1		Ausencia de metabolitos anormales	Normal

RESULTADOS NORMALES

Recuerde que estas son pruebas de tamizaje que solo indican la probabilidad de que el recién nacido tenga una de las enfermedades estudiadas por el programa y pueden requerir pruebas adicionales para la confirmación de algún diagnóstico. La sensibilidad de estas pruebas se reduce a medida que aumenta la edad del paciente, por esto es conveniente realizarlas dentro del primer mes de nacido.

REVISADO : EDUVILIA JOHANA GOMEZ
Bacterióloga
Reg. 40.936.003

PROCESADO : MARIA JOSE PINZON GARCIA
Bacterióloga
Reg. 1.015.469.392

FECHA : 16/07/2026

- - - - - - - - - - - - - - - - - - - -

`LABORATORIO PREGEN
Carrera 15a No 106-42
BOGOTA

Batch 2192, Rack A, Plate 1, Well B09, 173397-2MX AF
[8D298510090AC668] Jul 06, 2026 15:31:33 Pressure = 80 bar (77 to 81)



PEAK	RT	REL RT	% CONC	AREA	COMMENT
1	0.408	F 0.22	3.0%	48775	
2	0.513	F 0.28	1.9%	31055	
3	0.803	F 0.44	1.9%	31475	
4	1.160	F 0.64	0.3%	5533	
5	1.285	F 0.71	0.6%	9235	
6	1.662	F 0.91	0.4%	6488	
7	1.905	F 1.05	2.7%	44717	6
8	2.603	F 1.43	9.9%	160837	3
9	3.515	A 1.00	77.0%	1255012	2 A peak
10	4.390	S 0.86	2.3%	36972	
			Total Area:	1630099	

Codes:
1) Wide A peak
2) Area of A peak < 80%
3) Peak area greater than expected
4) Peak after A2
5) A1c > 10%
6) HbF or variant present
7) Total sample area too small/big
8) A2 is not within normal range

baby health check©

+ARCHIMEDlife Laboratory has been designated as a medical laboratory with the identification number 0407 from Accreditation Austria/Federal Ministry for Digitization and Business Location for the areas listed and published at: www.bmaw.gv.at/akkreditierung.

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGEN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report	29.05.2026
Sample Received	20.05.2026
Date of Sampling	13.05.2026
LAB-ID	262022211

Medical Report

Patient name	**AREVALO SANCHEZ MIA ANTONELLA**
Date of Birth	**22.02.2026**

Sample-ID	A0361355
Gender	F

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot. qPCR from Dried Blood Spot.

Results:

Parameter	Value	Unit	Reference
Birth weight (g)	3180	g	-
17-hydroxyprogesterone (17OHP)	<5.0	nmol/L	< 90.0
Thyroid-stimulating hormone (TSH)	<0.7	µU/mL	< 15.0
Biotinidase	219.5	U	> 51.0
Galactose-1-P-uridyltransferase (GALT)	6.7	U/g Hb	> 2.5
Immunoreactive trypsinogen (IRT)	<15	ng/mL	< 65.0
Phenylalanine	41.3	µmol/L	< 150.0
Amino acid profile	negative		-
Acylcarnitine profile	negative		-

Interpretation: NEGATIVE RESULT

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife®
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria | www.archimedlife.com

Patient name	**AREVALO SANCHEZ MIA ANTONELLA**	Sample-ID	A0361355
Date of Birth	**22.02.2026**	Gender	F

Results:

Amino Acids

Parameter	Value	Unit	Reference
Phenylalanine (Phe)	41.3	µmol/L	< 150.0
Phenylalanine / Tyrosine ratio (Phe/Tyr)	0.48	µmol/L	< 2.20
Tyrosine (Tyr)	86.7	µmol/L	< 200.0
Leucine (Leu)	132.5	µmol/L	< 270.0
Valine (Val)	60.8	µmol/L	< 200.0
Methionine (MET)	19.7	µmol/L	< 78.0
Methionine / Phenylalanine (Met/Phe)	0.48	µmol/L	< 1.60
Citrulline (Cit)	12.0	µmol/L	< 50.0
Ornithine (Orn)	189.8	µmol/L	< 250.0
Ornithine / Citrulline ratio (Orn/Cit)	15.82	µmol/L	1.50 - 20.00
Proline (Pro)	107.1	µmol/L	< 350.0
Alanine (Ala)	246.7	µmol/L	< 750.0
Arginine (Arg)	28.4	µmol/L	< 100.0
Aspartic acid (Asp)	91.4	µmol/L	< 100.0
Glutamic acid (Glu)	269.9	µmol/L	< 600.0
Glycamine (Gly)	319.9	µmol/L	< 700.0

Acylcarnitines

Free carnitine (C0)	27.56	µmol/L	6.00 - 100.00
acetylcarnitine (C2)	15.84	µmol/L	1.34 - 48.81
propionylcarnitine (C3)	2.27	µmol/L	0.13 - 6.60
butyryl-/isobutyrylcarnitine (C4)	0.14	µmol/L	0.03 - 0.90
isovaleryl-/2-methylbutyrylcarnitine(C5)	0.53	µmol/L	0.02 - 2.00
tiglylcarnitine (C5:1)	0.02	µmol/L	< 0.20
hydroxyvalerylcarnitine (C5OH)	0.36	µmol/L	0.02 - 0.57
glutarylcarnitine (C5DC)	0.03	µmol/L	< 0.30
hexanoylcarnitine (C6)	0.04	µmol/L	0.01 - 0.13
octanoylcarnitine (C8)	0.03	µmol/L	0.01 - 0.30
decanoylcarnitine (C10)	0.03	µmol/L	0.01 - 0.36
decenoylcarnitine (C10:1)	0.08	µmol/L	< 0.30
dodecanoylcarnitine (C12)	0.07	µmol/L	0.10 - 0.60
myristoylcarnitine (C14)	0.17	µmol/L	0.01 - 0.57
tetradecenoylcarnitine (C14:1)	0.08	µmol/L	0.10 - 0.38
palmitoylcarnitine (C16)	1.31	µmol/L	0.62 - 7.81
3-hydroxypalmitoylcarnitine (C16OH)	0.02	µmol/L	< 0.10
stearoylcarnitine (C18)	0.68	µmol/L	0.30 - 2.40
oleylcarnitine (C18:1)	3.50	µmol/L	0.06 - 3.86
3-hydroxystearoylcarnitine (C18OH)	0.01	µmol/L	< 0.09
malonylcarnitine (C3DC)	0.04	µmol/L	< 0.50

Amino acid levels are indicators of phenylketonuria, tyrosinemia, MSUD, hydroxyprolinuria, hypermethioninemia (homocystinuria), citrullinemia, argininosuccinate aziduria, hyperargininemia, and hyperprolinemia. Acylcarnitine levels are indicators of carnitine uptake disorders, CPT-I deficiency, CPT-II deficiency, CAT deficiency, propionaciduria, methylmalonic aciduria, malonic aciduria, SCAD deficiency/ethylmalonic aciduria, isovaleric aciduria, HMG-CoA lyase deficiency, 3-methylcrotonyl-CoA carboxylase deficiency, methylglutaconiciduria, MCAD deficiency, VLCAD deficiency, LCHAD deficiency, glutaraziduria I, multiple acyl-CoA dehydrogenase deficiency (MAD deficiency/glutaraziduria II), and Beta-ketothiolase deficiency.

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife GmbH
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria
www.archimedlife.com